本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
BEIJING, April 18, 2025 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the Securities and Exchange Commission on April 18, 2024. The annual report is available on the Company's investor relations website at https://ir.soyoung.com/. The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be submitted to ir@soyoung.com. About So-Young International Inc. So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company") is the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments. The Company provides access to aesthetic treatments through its online platform and branded aesthetic centers, offering curated treatment information, facilitating online reservations, delivering high-quality treatments, and developing, producing and distributing optoelectronic medical equipment and injectable products. With its strong brand recognition, digital reach, affordable treatments and efficient supply chain, So-Young is well-positioned to serve its audience over the long term and grow along the medical aesthetic value chain. Safe Harbor Statement This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young's strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young's beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young's strategies; So-Young's future business development, financial condition and results of operations; So-Young's ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young's revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law. For more information, please contact:So-Young Investor RelationsMs. Mona QiaoPhone: +86-10-8790-2012E-mail: ir@soyoung.com Christensen In ChinaMs. Dee WangPhone: +86-10-5900-1548E-mail: dee.wang@christensencomms.com In USMs. Linda BergkampPhone: +1-480-614-3004Email: linda.bergkamp@christensencomms.com
Showcasing at ASCRS 2025: More than 2 million cases planned with ZEISS VERACITY Surgery Planner: Growing use of one of the leading digital planning solutions for cataract surgery in the U.S. is a testament to the increased adoption of the ZEISS Cataract Workflow digital solutions by surgeons. ZEISS MEL 90 broadens refractive treatment portfolio: U.S. availability of both the ZEISS MEL 90 and ZEISS VISUMAX 800 extends the company's LVC market leadership with treatments for myopia, hyperopia, and mixed astigmatism. Enhanced cataract portfolio with DORC and FCI: Showcasing cataract solutions from DORC and FCI for the first time in the ZEISS booth #1501. JENA, Germany and DUBLIN, Calif., April 17, 2025 /PRNewswire/ -- ZEISS Medical Technology will celebrate the rapid adoption of digital cataract solutions and showcase newly available refractive treatment technology at the American Society of Cataract and Refractive Surgery (ASCRS) conference from April 25 – 27 in Los Angeles, CA. ZEISS marks a major milestone in the U.S. with more than 2 million digitally planned cases using the ZEISS VERACITY Surgery Planner,1 one of the leading digital planning solutions for cataract surgery, which serves as a testament to the growing number of surgeons discovering the benefits of digital workflows in the delivery of patient care and treatments. ZEISS VERACITY Surgery Planner "The digital era continues to grow at a rapid pace. Ophthalmologists are increasingly realizing the significant benefits of using digital workflows as the backbone of their medical practices," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "ZEISS has much to celebrate at ASCRS this year, including our continued U.S. leadership in digital innovation and ongoing commitment to improving patient care across both the cataract and refractive markets." Additionally, the ZEISS Refractive Workflow will showcase for the first time both the VISUMAX® 800 with SMILE® pro from ZEISS and the MEL® 90 from ZEISS, helping to further broaden a surgeon's refractive business with improved patient attraction and positive clinical outcomes. Lastly, for the first time, DORC and FCI, both ZEISS companies, are set to present their portfolio of cataract surgical solutions in the ZEISS booth, showcasing the extended benefits of ZEISS's surgical portfolio. More than 2 million cases planned using ZEISS VERACITY Surgery Planner reflects growing digital adoption by U.S. cataract surgeons ZEISS VERACITY Surgery Planner is one of the top digital planning solutions for cataract surgery in the U.S. today with thousands of users logging in to plan their surgical cases, pulling data from most modern EMRs, 19 different diagnostic devices, and optional data sources like patient questionnaires, in order to make data-driven informed decisions designed to drive better patient outcomes in clinics and ORs. At ASCRS, ZEISS will celebrate the significant milestone of its cloud-based ZEISS VERACITY Surgery Planner, with more than 2 million cases planned. A recent study showed that with the ZEISS Cataract Workflow powered by ZEISS VERACITY Surgery Planner, surgeons and staff can save up to 60% of their time per eye compared to traditional paper planning.2 Kerry Solomon, MD, from Carolina Eye Care Physicians, one of the creators of VERACITY prior to its acquisition by ZEISS in 2017, says, "Today we're up to 2 million plans, unbelievable! When we first started developing this solution, I absolutely envisioned we'd get to where we are today, and I'm thrilled with where we're at!" In addition to proven efficiency gains, new research abstracts presented at this year's ASCRS showcase excellent refractive accuracy and clinical outcomes when adopting the ZEISS Cataract Workflow: Steven C. Schallhorn, MD, ABO, will present a clear benefit of reducing postoperative astigmatism by implanting toric IOLs in patients with lower preoperative corneal astigmatism, leveraging cataract outcomes obtained from VERACITY Surgery Planner's database of 50,850 eyes with preoperative corneal astigmatism between 0.75D and 1.50D. Luke Rebenitsch, MD, ABO, will present a comparison of refractive outcomes in a large cohort of 49,057 eyes undergoing cataract surgery with toric IOL implantation where the use of the ZEISS CALLISTO eye system resulted in significant improvements in terms of post-op refractive outcomes compared to a manual marking approach. Kamran M. Riaz, MD, ABO, will present an analysis of the refractive accuracy of two biometers in a cohort of 222 eyes with prior laser vision correction and implantation of toric multifocal IOLs, highlighting the significantly better performance of total keratometry with the IOLMaster 700. Enhanced refractive treatment portfolio enables a higher standard of refractive patient care with both the ZEISS VISUMAX 800 and ZEISS MEL 90 ZEISS continues to set high standards in refractive patient care in the U.S. with the availability of both the ZEISS VISUMAX 800 and ZEISS MEL 90. For the first time, the ZEISS MEL 90 will be showcased in the U.S. at ASCRS, extending ZEISS's LVC market leadership with treatment for myopia, hyperopia, and mixed astigmatism. "The FDA approval of the ZEISS MEL 90 excimer laser is a game changer for refractive surgery in the U.S. I am particularly impressed by the system's ability to simplify treatment planning while delivering highly predictable and tissue-conserving results. This approval marks an exciting chapter for surgeons and patients alike," says Dr. John Doane, Refractive Surgeon, Discover Vision Centers, Kansas City, MO (USA). The MEL® 90 from ZEISS aims to offer U.S. surgeons a fast, reliable, and streamlined surgery experience, complementing the VISUMAX® 800 with SMILE® pro from ZEISS to help further broaden a surgeon's refractive business with improved patient attraction and positive clinical outcomes. The ZEISS VISUMAX 800 with ZEISS SMILE pro software enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.3 The ZEISS femtosecond laser also provides greater flexibility for the surgeon and patient, with a smaller footprint and compatibility with a variety of patient beds, adapting to the clinical environment to provide cutting-edge technology without compromise. Showcasing the benefits of ZEISS's surgical portfolio to help meet the evolving clinical challenges of surgeons in the U.S. ZEISS will showcase for the first time together in the ZEISS booth key solutions from DORC and FCI. This will feature the DORC EVA NEXUS™ surgical system for cataract and phaco-vitrectomy surgeries. It will also include the DORC VisionBlue® anterior stain, a trusted choice in more than 10 million cataract surgeries since its introduction. As the only FDA-approved trypan blue stain for anterior applications, it is also authorized for staining Descemet's membrane and trabecular meshwork. Additionally, the ZEISS booth will feature the FDA-approved Eyejet® 20C from Morcher®, built on the gold standard preloaded Eyejet® system and designed to prevent toric IOLs rotation, providing maximum toric benefits. ZEISS will showcase its latest offerings and new innovations at the American Society of Cataract and Refractive Surgery (ASCRS) conference from April 25-27, 2025, in Los Angeles, CA, at booth #1501. For more information, visit www.zeiss.com/med. 1 Data on file.2 Gujral, Tarika, and John Hovanesian. "Cataract Surgical Planning Using Online Software vs Traditional Methods." Clinical Ophthalmology (Auckland, N.Z.), U.S. National Library of Medicine, 28 July 2021.3 Data on file, myopia with optical zone 6.5 mm. Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: investors.meditec@zeiss.com Contact for the pressFrank SmithHead of Global Communications OphthalmologyCarl Zeiss Meditec Inc.Phone: +49 3641 220 331Mail: press.med@zeiss.com www.zeiss.com/newsroom Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.For further information visit: www.zeiss.com/med ZEISS MEL 90 Excimer Laser
ZHUBEI, April 17, 2025 /PRNewswire/ -- Brain Navi Biotechnology Co., Ltd. ("Brain Navi") has officially begun IPO counseling with First Securities Inc., marking a strategic step toward accessing the capital markets and advancing its long-term growth in the surgical robot technology industry. Dr. Jerry Chen, CEO of Brain Navi, announced the IPO Consulting to enter the capital market. Founded in 2015 and located in the Hsinchu Biomedical Science Park, Brain Navi concentrates on innovating surgical robots and medical devices. By integrating machine vision, artificial intelligence (AI), and advanced navigation technologies, the company provides high-precision surgical solutions tailored to meet the evolving needs of modern healthcare. Over the years, Brain Navi has established strong partnerships with leading medical institutions worldwide. Its innovations have garnered multiple international patents and regulatory approvals, with global expansion efforts already underway in Europe, Asia, Latin America, and soon in the USA market. The company's flagship product, NaoTrac, is a neurosurgical navigation robot that combines AI, robotics, and computer vision to enhance surgical precision and reduce operative time. Brain Navi's portfolio also includes the KrystoLens, the single-use neuro-endoscope designed to improve safety and efficiency in minimally invasive brain surgery. Looking ahead, Brain Navi plans to deepen collaborations with top-tier medical centers to refine its intelligent surgical systems. Through this IPO counseling process, the company aims to responsibly accelerate R&D and scale its innovations for broader clinical adoption, reinforcing its position as a next-generation leader in smart medical technology. First Securities Inc. expressed confidence in Brain Navi's growth potential. As global interest in surgical robotics continues to rise—especially in neurosurgery, where accuracy is critical—technologies that combine navigation and AI are poised to play a transformative role. The firm will provide continued guidance throughout Brain Navi's IPO journey, helping bring new investment opportunities to those who share a vision for the future of intelligent healthcare.
Silicone, an indispensable material in modern life, stands out in the fields of healthcare, electronics, food, and industry due to its unique properties, including high and low-temperature resistance, non-toxicity, waterproofing, and high elasticity. From everyday food grade utensils to high-precision medical implants, and liquid silicone components that enhance automotive performance, the diverse applications of silicone continue to revolutionize our imagination. This article will delve into the types, characteristics, and wide-ranging applications of silicone, uncovering the mysteries of advanced materials such as platinum-cured silicone, medical-grade silicone, and liquid silicone. It will also compare silicone with similar materials like TPE and latex, providing a comprehensive guide to help you make the most informed product choices. What You Should Know About Silicone Rubber Silicone is not plastic. Its exceptional resistance to extreme temperatures (from -40 to 220°C), non-toxicity, waterproof nature, and high flexibility have made it a star material in medical, electronic, food, and industrial applications. Made from natural silica, silicone is not only safe and non-toxic but also food grade and remarkably stable even in harsh environments. Available in liquid, solid, and foam forms, each type of silicone offers unique benefits in terms of elasticity, strength, and shock absorption. Unlike plastic, which can release toxins and is difficult to decompose, silicone is eco-friendly and durable—making it a safer and more sustainable choice for modern living. In this article, we’ll debunk common myths about silicone and give you a fresh look at this material of the future. Is Silicone Toxic? A Comprehensive Analysis of Silicone Safety Silicone is a versatile polymer material widely used in various aspects of daily life, commonly found in kitchenware, medical devices, and baby products. Food grade and medical-grade silicone are considered safe because they are non-toxic, odorless, heat-resistant, and do not release harmful substances, meeting international safety standards. However, there are also some low-quality products on the market that may contain harmful chemicals, requiring caution during use. Choosing certified brands and carefully reviewing product labels is an effective way to ensure safety. In conclusion, selecting and using silicone products correctly allows you to fully enjoy their convenience and safety. How to distinguish food grade silicone and regular silicone? With growing awareness of food safety, silicone eco-friendly tableware has become a popular alternative to disposable plastic. The key differences between food grade silicone and regular silicone lie in their manufacturing processes, ingredients, and certifications. Food grade silicone undergoes strict testing, uses high-quality imported raw materials, and is certified by international standards such as the FDA and NSF to ensure it is safe for contact with food. Its advantages include high heat resistance, non-toxicity, less odor, and chemical stability, making it suitable for use in tableware, baking tools, and baby products. In contrast, regular silicone is commonly used in industrial products and subject to less stringent quality requirements. Choosing food grade silicone not only protects your health but also aligns with modern demands for environmental sustainability and safety. What is platinum silicone and how safe it is? Platinum silicone is widely used in medical, food, and infant products due to its exceptional safety and stability. This type of silicone is free of metals and uses platinum as a catalyst during the manufacturing process, giving the product a higher temperature resistance range (-40°C to 260°C) and ensuring no harmful substances are released. In addition to its high temperature resistance, platinum silicone also offers excellent breathability, effectively reducing odor retention, making it more suitable for food containers. Compared to regular silicone, platinum silicone has stronger chemical stability, allowing it to better withstand rapid temperature changes and resist corrosion from cleaning agents, ensuring greater durability. As consumers increasingly prioritize health and environmental concerns, more and more manufacturers are choosing platinum silicone to offer safer products to consumers. Medical Grade Silicone: How to define it? Medical-grade silicone is widely used in medical devices and implants due to its excellent biocompatibility and safety. Unlike regular silicone, medical-grade silicone undergoes rigorous testing to ensure it is non-toxic, non-irritating, and hypoallergenic, meeting international certification standards such as FDA and LFGB. These silicone materials offer superior resistance to temperature, bacteria, and radiation, making them suitable for high temperatures, repeated sterilization, and various medical environments. They are used in medical equipment such as respiratory masks, infusion tubes, and implants, ensuring safety for the human body and compliance with medical device regulations. Glory Sun Group focuses on providing medical-grade silicone products that meet international standards, offering high quality and timely supply to meet market demand. How to choose between TPE and Silicone Rubber? Find out their respective characteristics! TPE (Thermoplastic Elastomer) and silicone are two common high-performance materials, each with its own characteristics and advantages. TPE offers excellent elasticity, is cost-effective, and is widely used in applications such as automotive parts, sports equipment, and medical devices. On the other hand, silicone excels in high-temperature resistance and safety, making it commonly found in medical products, baby products, and food grade kitchenware. When selecting a material, the product's specific application needs should be considered. If flexibility and elasticity are a priority, TPE is the ideal choice; if the product needs to withstand high temperatures and offer long-term durability, silicone is recommended. Regardless of the material chosen, it is crucial to find a manufacturer with extensive experience to ensure product quality and production stability. What's the Difference Between Silicone & Latex Silicone and latex are two commonly used high-elasticity materials widely applied in mattresses, medical devices, and everyday products. Silicone, made from silica, is known for its high stability, water resistance, and electrical insulation, making it ideal for use in medical, food grade, automotive, and electronic products. In contrast, latex is derived from natural tree sap and offers excellent elasticity, often used in mattresses, hygiene products, and medical gloves. Silicone is more resistant to high temperatures and chemical exposure, making it suitable for extreme environments, while latex, with its superior flexibility, is ideal for products that require prolonged skin contact. Choosing the right material depends on the specific application needs. In both the medical and food industries, products made from these materials must comply with FDA regulations to ensure safety. High-Temperature Silicone: Characteristics, Applications, and Buying Guide High-temperature silicone plays a crucial role in modern industries due to its exceptional heat resistance, stability, and versatility. It can withstand temperatures up to 300°C or even higher, maintaining its physical and chemical properties. It is widely used in fields such as electronics, automotive, healthcare, food processing, and aerospace. In these industries, high-temperature silicone provides reliable insulation, chemical resistance, and high elasticity, ensuring stable operation of equipment in high-temperature environments. Additionally, the non-toxicity and aging resistance of this material make it especially important in medical devices and food processing. When selecting the appropriate high-temperature silicone products, factors such as temperature range, certification standards, and chemical compatibility should be considered to ensure optimal performance and long-term stability. Applications of Liquid Silicone Rubber Injection Molding in smart clothing Liquid Silicone Rubber (LSR) injection molding technology is increasingly becoming a key material in high-performance sports equipment, offering exceptional comfort, durability, and anti-slip properties. Its advantages include the ability to create precision and complex structures with extremely high elasticity and weather resistance, making it particularly suitable for insoles, knee and elbow pads, and other sports protective gear. Additionally, the integration of liquid silicone rubber with knitted fabrics enhances both the functionality and aesthetics of the products, providing designers with greater room for innovation. These technologies not only improve the protective performance of sports equipment but also ensure long-term reliability, thus enhancing athletic performance and safety. With the advancement of liquid silicone rubber technology, it is expected to play an even greater role in the sports equipment sector, delivering higher-performance products for consumers. Medical Grade Silicone: How to define it? Medical-grade silicone is widely used in medical devices such as respiratory masks, infusion tubes, and implants due to its high biocompatibility, non-toxicity, and hypoallergenic properties, ensuring safety for human use. This type of silicone must pass rigorous testing, including certifications like FDA or LFGB, to confirm its compliance with medical or food-contact standards. Key features of medical-grade silicone include resistance to extreme temperatures, excellent antimicrobial properties, and radiation resistance, making it suitable for repeated disinfection and sterilization processes. Its applications range from medical components to short-term and long-term implants. The Future of Liquid Silicone in Automotive Applications Liquid silicone, as a high-tech material, is increasingly being used in the automotive manufacturing industry to enhance vehicle performance and safety. Its high-temperature resistance and excellent weatherability make it an ideal choice, especially for components such as body seals, lighting systems, electronic component packaging, and automotive glass. The use of liquid silicone not only improves sealing performance but also enhances the waterproofing of headlights and the stability of electronic systems. Furthermore, its lightweight properties help reduce vehicle weight, improve fuel efficiency, and lower carbon emissions, thereby enhancing both vehicle safety and environmental friendliness. In the future, with ongoing technological advancements, liquid silicone will continue to drive innovation and breakthroughs in the automotive industry. Glory Sun Group offers strong technical expertise and quality assurance, and we sincerely welcome your inquiries! In conclusion, silicone's remarkable properties drive diverse applications across healthcare, electronics, food, and industry. Its temperature resistance, non-toxicity, and flexibility make it superior in many uses compared to materials like TPE and latex. For high-quality silicone solutions, feel free to visit the official website of Glory Sun Group. Glory Sun Group Contact Info: 1. TEL: +86-512-5777-7921 2. ADDR.: No.1288-1, Shuixiu Rd., High-tech Industrial Park,Kunshan City, Jiangsu Province, China (PC: 215316)[View Map] 3. Email: yllin@glorysun.com.cn 4. FAX: +86-512-5777-7937
In the preliminary findings of a study conducted with the National Taiwan University Hospital, over 50% of sample cases were reclassified as HER2-expressing when 3D pathology was applied. HSINCHU, April 17, 2025 /PRNewswire/ -- JelloX Biotech Inc., a Taiwan-based startup at the forefront of cancer pathology, announced the preliminary results of a research collaboration with the National Taiwan University Hospital (NTUH) on breast cancer patients. The study found that JelloX's 3D pathology technology identified a significantly increased proportion of tumors with HER2-low and HER2-ultralow expression compared to conventional methods, demonstrating this technology's increased sensitivity and potential as a superior diagnostic tool for HER2 detection in breast cancers. This is a 3D fluorescent-stained image of mammary ducts from a breast cancer patient. Green areas indicate drug-targeted receptors. Unlike traditional 2D pathology, this reveals the spatial distribution of receptors, reducing the risk of misjudging treatment decisions. Contact JelloX at sales@jellox.com to explore partnerships and learn more about the company's cutting-edge 3D pathology technology. According to the US National Cancer Institute, breast cancer is the most prevalent form of cancer. However, the difficulty of precisely determining treatment has made the identification of HER2 expression essential. In HER2-low and HER2-ultralow metastatic breast cancer, the novel antibody-drug conjugate (ADC) Trastuzumab deruxtecan (T-DXd) has demonstrated robust efficacy over conventional chemotherapy. Yet considering HER2 spatial heterogeneity, traditional diagnostic methods have shown to be less precise than 3D pathology in detecting the presence of the HER2 protein. "For the specific challenges posed by metastatic breast cancer and the need to identify predictive biomarkers accurately, the high sampling capacity of 3D pathology holds particular potential," commented Dr. Yen-Yin Lin, CEO of JelloX. "JelloX Biotech's Comprehensive HER2 Diagnostic Solution is poised to revolutionize HER2 diagnostics. With a more comprehensive data set on tumor samples, healthcare providers can be empowered to make more precise diagnoses, ensuring that the right patients receive the right treatment at the right time." New findings with NTUH on HER2 breast cancer In JelloX's research collaboration with NTUH, preliminary findings indicate that more than half of the analyzed cases exhibited diagnostic discrepancies when re-evaluated using the company's advanced 3D pathology methods. Notably, among patients initially classified as HER2-null by traditional methods, more than 66.7% were reclassified as HER2-expressing (HER2-low or HER2-ultralow) using 3D technology, thereby becoming potentially eligible for T-DXd treatment. These findings echo the company's recent results using samples from colorectal and esophageal cancers, demonstrating that 3D pathology may have broader potential across various cancer types. The full findings will be shared at the Global Breast Cancer Conference in South Korea on April 17. https://gbcc.kr/Main.asp Implications for breast cancer treatment and drug guidelines T-DXd has demonstrated significant efficacy in tumors with HER2 expression. However, tumors classified as HER2-null under conventional pathological testing are ineligible for T-DXd treatment. By detecting HER2 more precisely using 3D pathology methods, we can identify more patients eligible for T-DXd therapy. In addition to cancer patients, JelloX's 3D pathology technology has the potential to expand possibilities across healthcare stakeholders: For physicians: This advanced diagnostic tool offers a more comprehensive patient data set and, when integrated with AI, helps reduce physician workloads. For pharmaceutical companies and research institutions: The technology enhances companion diagnostics (CDx) for drug usage and is a valuable tool for new drug development. For healthcare systems: 3D pathology optimizes medical resource allocation and minimizes unnecessary financial and healthcare burdens. About JelloX Biotech Inc. Based in Hsinchu, Taiwan, JelloX Biotech Inc. is a startup that focuses on advancing cancer pathology through 3D digital imaging and AI technology. For more information, please visit: https://jellox.com/en/home/
Daly, a 30-year veteran of the healthcare industry, is the latest leadership addition to help Terumo BCT unite business areas and fuel enterprise growth LAKEWOOD, Colo., April 17, 2025 /PRNewswire/ -- Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, today announced the addition of Patrick Daly as its Chief Business Officer as the company continues to expand its capabilities to meet evolving market segments. Daly joins Terumo BCT with over 30 years of business and healthcare industry experience, both domestically and internationally. Most recently, he built the MedTech Global Data franchise at IQVIA, a provider of technology solutions to the life sciences industry. Daly has spent his career building commercial capabilities to deliver organic and inorganic growth. Before joining IQVIA, he was President and CEO of Cohera Medical, and he remains an independent Board Director for BioStem Technologies. He has held successive senior leadership roles in strategic marketing, sales and business development across various regions and businesses of Johnson & Johnson. He earned his Bachelor of Science in Foreign Area Studies from the U.S. Military Academy at West Point. "Patrick's experience acquiring capital and building strategic partnerships complements his experience monetizing data and solutions. This uniquely positions him to integrate our offerings and drive innovation across our business models and go-to-market strategies," said Antoinette Gawin, President and Chief Executive Officer of Terumo BCT. "His diverse experience will help accelerate our ambitions for double-digit growth." "It is a great moment to join Terumo BCT as it continues executing its long-term vision for growth and to meet patients' unmet needs globally," said Daly. "I am focused on ensuring our full portfolio, connected with data, software and services, will play a growing role in helping our customers solve healthcare's toughest challenges, while advancing disease research, therapeutic development and improved access to safe blood worldwide." About Terumo Blood and Cell Technologies Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees worldwide believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers. Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 150 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending. We have global headquarters in Lakewood, Colorado, U.S.A., along with five regional headquarters, eight manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.
A12 藝術空間
Medical Equipment
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
